NITTO BOSEKI CO., LTD.
3110・Prime Market・Glass & Ceramics Products
Electronic Materials Business
Nitto Boseki's core profit-generating segment. High growth driven by Special Glass for AI servers and semiconductors.
| Period | Current | Previous | Change |
|---|---|---|---|
| Net Sales (Full Year FY2026, ending March 2026) | ¥49,265 million | ¥40,911 million | ↑ |
| Operating Income (Full Year FY2026, ending March 2026) | ¥19,391 million | ¥13,880 million | ↑ |
| Operating Margin (Full Year FY2026, ending March 2026) | 39.4% | 33.9% | ↑ |
| Segment Assets (as of end of FY2026, ending March 2026) | ¥129,381 million | ¥102,912 million | ↑ |
| Depreciation (Full Year FY2026, ending March 2026) | ¥7,229 million | ¥5,849 million | ↑ |
| Increase in Property, Plant and Equipment and Intangible Assets (Full Year FY2026, ending March 2026) | ¥18,691 million | ¥10,072 million | ↑ |
Business Details
This segment develops, manufactures, and sells glass fiber products for electronic materials applications. It maintains an integrated production system encompassing both glass fiber yarn manufacturing and glass cloth processing. Centered on specially formulated Special Glass with low dielectric and low thermal expansion properties, the segment expands into the printed wiring board materials field, AI server applications, and semiconductor package substrate applications. It operates globally in collaboration with domestic and overseas affiliated companies. In FY2026 (ending March 2026), this segment accounted for approximately 41.7% of consolidated net sales, making it the company's core profit segment.
Recent Overview
Robust AI server demand drove strong Special Glass sales, resulting in substantial increases in both net sales and operating income.
In FY2026 (ending March 2026), sales of low dielectric Special Glass and low thermal expansion Special Glass for semiconductor package substrates trended favorably, driven by continued robust demand from AI servers. Net sales reached ¥49,265 million (up 20.4% year on year), and operating income reached ¥19,391 million (up 39.7% year on year), achieving substantial profit growth. Capital expenditure also expanded to ¥18,691 million, approximately 1.9 times the prior year's level, as the company actively pursues capacity expansion investments toward FY2027 (ending March 2027).
Key Products
Growth Drivers
- Expanded sales of low dielectric Special Glass driven by continued robust demand for AI servers
- Increased demand for low thermal expansion Special Glass for semiconductor package substrates
- Capacity expansion investments from FY2027 (ending March 2027) onward, driven by data center server and network equipment demand (capital expenditure forecast of ¥45,000 million for FY2027, ending March 2027)
- Shift toward high-value-added products driven by the sophistication of information and communications infrastructure
- Competitive advantage from an integrated production system spanning glass fiber yarn manufacturing and glass cloth processing
- Active pursuit of investment in expanding Special Glass production capacity under the Medium-Term Management Plan (FY2024-FY2027)
Risks
- Risk of technological catch-up progress by domestic and overseas competitors
- Risk of demand fluctuation in the AI server and semiconductor markets (dependence on specific markets)
- Uncertainty in demand due to geopolitical risks such as China's economic slowdown and U.S. tariff policy
- Risk of profit pressure from soaring raw material and energy costs
- Foreign exchange fluctuation risk at overseas locations in Taiwan, China, and elsewhere
- Investment recovery risk associated with large-scale capital expenditure (forecast of ¥45,000 million for FY2027, ending March 2027)
Medical Business
A stable revenue-generating segment responsible for the development, manufacture, and sale of in vitro diagnostic reagents.
| Period | Current | Previous | Change |
|---|---|---|---|
| Net Sales (Full Year, FY2026 ending March 2026) | ¥13,850 million | ¥13,603 million | ↑ |
| Operating Income (Full Year, FY2026 ending March 2026) | ¥2,431 million | ¥2,381 million | ↑ |
| Segment Assets (as of end of FY2026, ending March 2026) | ¥24,015 million | ¥22,855 million | ↑ |
| Depreciation (Full Year, FY2026 ending March 2026) | ¥751 million | ¥642 million | ↑ |
| Increase in Property, Plant and Equipment and Intangible Assets (Full Year, FY2026 ending March 2026) | ¥923 million | ¥803 million | ↑ |
Business Details
This segment develops, manufactures, and sells in vitro diagnostic reagents and related products. It is centered on Nittobo Medical Co., Ltd. (domestic) and Nittobo America Inc. (U.S., manufacturing and sale of antiserum products). Through integrated in-house manufacturing from raw materials to final products, the segment achieves both high quality and stable supply, securing a significant domestic market share in immunodiagnostic reagents (inflammation markers, osteoporosis markers, etc.). Domestically, it offers diagnostic reagents covering over 100 test items, while overseas it pursues a strategy of capturing high-value-added medical demand in developed countries and expanding diagnostic opportunities in emerging countries.
Recent Overview
Despite headwinds from China's preference for domestically produced products, sales of in vitro diagnostic reagents remained solid; base strengthening continued.
In FY2026 (ending March 2026), despite headwinds from the advancing preference for domestically produced products in the Chinese market, sales of in vitro diagnostic reagents and related products remained solid. Net sales reached ¥13,850 million (up 1.8% year on year) and operating income reached ¥2,431 million (up 2.1% year on year), achieving modest but positive growth in both revenue and profit. Base strengthening efforts also continued, with segment assets increasing by ¥1,160 million from the prior year-end to ¥24,015 million. Capital expenditure (increase in property, plant and equipment and intangible assets) also expanded to ¥923 million, up from ¥803 million in the prior year.
Key Products
Growth Drivers
- Expanding demand for higher-functionality diagnostic reagents driven by an aging population and the shift from treatment to prevention
- Increasing demand for high-value-added medical care in developed countries, including high-sensitivity immunodiagnostic reagents, infectious disease testing, and genetic testing
- Increased diagnostic opportunities and expansion of the in vitro diagnostic reagent market in emerging countries as social insurance systems are established
- Competitive advantage from an integrated manufacturing system from raw materials to final products, achieving high quality and stable supply
- Continued active capital expenditure and base strengthening under the Medium-Term Management Plan (FY2024-FY2027)
Risks
- Risk of losing sales opportunities due to the advancing preference for domestically produced products in the Chinese market
- Profit pressure from global inflation and soaring raw material and energy costs
- Impact on overseas sales and costs from unstable foreign exchange rates
- Intensifying technological catch-up and price competition from domestic and overseas competitors
- Downward pressure on diagnostic reagent prices from healthcare cost containment policies
Composite Materials Business
A business that develops, manufactures, and sells glass fiber products for plastic reinforcement material applications
| Period | Current | Previous | Change |
|---|---|---|---|
| Net Sales | ¥13,401 million (Full Year, FY2026 ending March 2026) | ¥13,474 million (Full Year, FY2025 ending March 2025) | ↓ |
| Operating Loss | -¥122 million (Full Year, FY2026 ending March 2026) | -¥900 million (Full Year, FY2025 ending March 2025) | ↑ |
| Segment Assets | ¥20,174 million (as of end of FY2026, ending March 2026) | ¥18,568 million (as of end of FY2025, ending March 2025) | ↑ |
| Depreciation | ¥136 million (Full Year, FY2026 ending March 2026) | ¥180 million (Full Year, FY2025 ending March 2025) | ↓ |
Business Details
This business develops, manufactures, and sells glass fiber products for plastic reinforcement material applications. It offers a wide range of products for FRP (Fiber Reinforced Plastic) and FRTP (Fiber Reinforced Thermoplastic Plastic) applications, including Flat Fiber, which features an oval cross-section achieved through proprietary technology. While the business can capture needs related to automobile weight reduction and environmentally friendly products, the competitive environment for commodity products remains challenging due to the rise of Chinese manufacturers. Fuji Fiber Glass Co., Ltd., an affiliated company, sells glass fiber products to the company.
Recent Overview
Sales remained roughly flat year on year, but the operating loss narrowed substantially as the cost increase from periodic equipment maintenance dissipated.
In FY2026 (ending March 2026), the Composite Materials Business recorded net sales of ¥13,401 million (down 0.5% year on year), with sales remaining roughly at the prior year's level. On the other hand, the operating loss narrowed substantially to ¥122 million (compared to an operating loss of ¥900 million in the prior year), as the impact of the cost increase from periodic equipment maintenance incurred in the prior year dissipated. Segment assets increased by ¥1,606 million from the prior year-end to ¥20,174 million.
Key Products
Growth Drivers
- Increased demand for glass fiber for FRP and FRTP applications driven by expanding needs for automobile weight reduction
- Expanding needs for environmentally friendly products (support for mass-balance recycled products through ISCC PLUS certification)
- Differentiation through proprietary technology products such as Flat Fiber
- Profit improvement from the dissipation of periodic equipment maintenance costs (the loss narrowed substantially in FY2026, ending March 2026)
Risks
- Intensifying competition and downward price pressure on commodity products from the rise of Chinese manufacturers
- Periodic cost increases associated with regular equipment maintenance
- Soaring raw material and energy costs
- A history of recording a large-scale impairment loss in FY2025 (ending March 2025), indicating a realized risk of asset value impairment
- Net sales showing a slight year-on-year decline, indicating a lack of robust demand recovery
Materials & Chemicals Business
A segment securing stable revenue through diversified operations in industrial materials, chemicals, and textiles
| Period | Current | Previous | Change |
|---|---|---|---|
| Net Sales (Full Year, FY2026 ending March 2026) | ¥9,515 million | ¥9,431 million | ↑ |
| Operating Income (Full Year, FY2026 ending March 2026) | ¥588 million | ¥839 million | ↓ |
| Segment Assets (as of end of FY2026, ending March 2026) | ¥10,791 million | ¥11,118 million | ↓ |
| Depreciation (Full Year, FY2026 ending March 2026) | ¥261 million | ¥281 million | ↓ |
| Increase in Property, Plant and Equipment and Intangible Assets (Full Year, FY2026 ending March 2026) | ¥437 million | ¥366 million | ↑ |
Business Details
This segment operates three businesses: the Glass Fiber Products for Industrial Materials Applications business, the Chemical business (Functional Polymers, inorganic-organic nanocomposite material SSG, etc.), and the Textile business (fusible interlining, functional materials, dishcloths, etc.). Because its customer base spans diverse industries, market fluctuations in individual industries are diversified, providing a structure that supports stable revenue recognition. The segment comprises nine affiliated companies, with Nittobo Advantex Co., Ltd. (interlining, functional materials, dishcloths) and Nitto Glass Tex Co., Ltd. (glass fiber products) as its main subsidiaries.
Recent Overview
Sales increased due to the effect of price hikes, but rising costs pressured profit, resulting in a decline in operating income.
Net sales for the full year FY2026 (ending March 2026) reached ¥9,515 million (up 0.9% year on year), slightly exceeding the prior year's level due to the effect of price increases. On the other hand, operating income declined substantially to ¥588 million (down 29.9% year on year). The primary cause was the impact of cost increases, mainly in raw materials, which pressured profitability. Segment assets also contracted to ¥10,791 million compared to the prior year-end.
Key Products
Growth Drivers
- Profit improvement effect from sales price increases
- Diversification of market fluctuation risk through multi-application deployment of glass fiber for industrial materials
- Strengthening of R&D, manufacturing, and sales of highly proprietary products (such as SSG) in the Chemical business
- Deepening of existing business areas and exploration of new businesses under the Medium-Term Management Plan (FY2024-FY2027)
Risks
- Continued profit pressure from cost increases centered on raw materials (the primary cause of the 29.9% decline in operating income in FY2026, ending March 2026)
- Price competition for industrial materials glass fiber amid intensifying competition from alternative materials
- Market fluctuations in customer industries (despite diversification effects, risk of downturns in individual industries)
- Risk that the revenue-boosting effect of price increases may fail to fully offset cost increases, leading to declining profit margins
Insulation Materials Business
A business contributing to energy conservation through the development, manufacture, and sale of Glass Wool Insulation
| Period | Current | Previous | Change |
|---|---|---|---|
| Net Sales (Full Year FY2026, ending March 2026) | ¥15,136 million | ¥15,320 million | ↓ |
| Operating Income (Full Year FY2026, ending March 2026) | ¥202 million | ¥693 million | ↓ |
| Segment Assets (as of end of FY2026, ending March 2026) | ¥13,312 million | ¥12,934 million | ↑ |
| Depreciation (Full Year FY2026, ending March 2026) | ¥614 million | ¥639 million | ↓ |
| Increase in Property, Plant and Equipment and Intangible Assets (Full Year FY2026, ending March 2026) | ¥1,266 million | ¥708 million | ↑ |
Business Details
The Insulation Materials Business develops, manufactures, and sells High-Performance Insulation Materials for residential housing and buildings. As an industry pioneer that achieved Japan's first successful glass wool manufacturing in 1949, the business holds proprietary technology. Using recycled glass as a primary raw material, it achieves both energy conservation contributions and effective resource utilization. Through fiber refinement to improve insulation performance and the elimination of formaldehyde, the business works to reduce environmental impact and realize safe, comfortable living environments. The main subsidiary is Paramount Glass Manufacturing Co., Ltd.
Recent Overview
Sluggish residential sales combined with periodic equipment maintenance costs led to a substantial decline in operating income.
In FY2026 (ending March 2026), sales for residential housing applications continued to trend sluggishly, compounded by the impact of cost increases from periodic equipment maintenance. Net sales reached ¥15,136 million (down 1.2% year on year), and operating income deteriorated substantially to ¥202 million (down 70.8% year on year). This represented a decline of ¥491 million from the prior year's (FY2025, ending March 2025) operating income of ¥693 million, making it one of the segments with the most pronounced profit deterioration within the group.
Key Products
Growth Drivers
- Expanding demand for High-Performance Insulation Materials driven by strengthened energy conservation standards for residential housing and buildings
- Shift in product mix toward High-Performance Insulation Materials (fiber-refined, formaldehyde-free products)
- Appeal as an environmentally friendly product using recycled glass as its primary raw material
- Deepening of existing business areas and exploration of new business concepts under the Medium-Term Management Plan (FY2024-FY2027)
Risks
- Continued sluggishness in residential sales due to the slowdown in housing starts
- Profit pressure from soaring raw fuel and energy costs
- Temporary cost increases associated with periodic equipment maintenance
- Intensifying competition from alternative materials (such as foam-based insulation materials)
- The Insulation Materials Business is positioned outside the scope of active investment under the Medium-Term Management Plan, limiting growth investment
Other Businesses
A complementary segment encompassing Industrial Machinery & Equipment Engineering and an industrial materials specialized trading function
| Period | Current | Previous | Change |
|---|---|---|---|
| Net Sales (Full Year, FY2026 ending March 2026) | ¥17,059 million | ¥16,294 million | ↑ |
| Operating Income (Full Year, FY2026 ending March 2026) | ¥488 million | ¥409 million | ↑ |
| Segment Assets (as of end of FY2026, ending March 2026) | ¥10,543 million | ¥9,888 million | ↑ |
| Depreciation (Full Year, FY2026 ending March 2026) | ¥47 million | ¥42 million | ↑ |
| Operating Margin (Full Year, FY2026 ending March 2026) | 2.9% | 2.5% | ↑ |
Business Details
The Other Businesses segment is centered on the design, manufacture, sale, construction, and maintenance services for industrial machinery and equipment. While supporting the maintenance of equipment and infrastructure within the group, it also serves as a specialized industrial materials trading function handling glass fiber products and other materials. It captures engineering demand associated with capacity expansion in the Electronic Materials Business, while playing a role in complementing the group's overall business foundation.
Recent Overview
Both net sales and operating income increased year on year, achieving a 19.3% year-on-year increase in operating income.
For the full year FY2026 (ending March 2026), net sales reached ¥17,059 million (up 4.7% year on year) and operating income reached ¥488 million (up 19.3% year on year). This is believed to have been driven by expanding intra-group engineering demand associated with capacity expansion in the Electronic Materials Business. Segment assets also increased by ¥655 million from the prior year-end to ¥10,543 million, reflecting continued gradual expansion in business scale.
Key Products
Growth Drivers
- Capturing intra-group capital expenditure demand (increased engineering demand associated with expanding capacity investment in the Electronic Materials Business)
- Brand unification and enhanced global expansion through the renaming to Nitto Boseki Global Trading Co., Ltd.
- Continued profit generation and customer base maintenance in industrial machinery and equipment-related businesses
Risks
- High dependence on intra-group demand, with performance influenced by capital expenditure trends in major business segments (particularly the Electronic Materials Business)
- In the specialized trading function, risk of market fluctuations in glass fiber products and price competition with competitors
- Limited scope for business scale expansion given the relatively small segment assets (¥10,543 million)
Life Science Business (Former Segment Classification)
A healthcare business segment that develops, manufactures, and sells in vitro diagnostic reagents and related products.
| Period | Current | Previous | Change |
|---|---|---|---|
| Net Sales (External Customers) | ¥13,850 million | ¥13,603 million | ↑ |
| Operating Income | ¥2,431 million | ¥2,381 million | ↑ |
| Net Sales, Year-on-Year Change | +1.8% | — | ↑ |
| Operating Income, Year-on-Year Change | +2.1% | — | ↑ |
| Segment Assets | ¥24,015 million | ¥22,855 million | ↑ |
| Depreciation | ¥751 million | ¥642 million | ↑ |
| Increase in Property, Plant and Equipment and Intangible Assets | ¥923 million | ¥803 million | ↑ |
Business Details
This is the current segment that carries on the functions of the former "Life Science Business." It is centered on the development, manufacture, and sale of in vitro diagnostic reagents and related products. Following the organizational restructuring in April 2024, the company transitioned to the current six-segment classification. Although headwinds persist in the Chinese market due to the advancing preference for domestically produced products, sales of in vitro diagnostic reagents and related products have remained solid, and base strengthening efforts continue. This business area plays a role in the Medium-Term Management Plan (FY2024-FY2027), which aims to achieve global niche No. 1 status.
Recent Overview
Despite headwinds from China's preference for domestically produced products, sales of in vitro diagnostic reagents remained solid, with continued base strengthening.
In FY2026 (ending March 2026), the Medical Business achieved modest but positive growth, with net sales of ¥13,850 million (up 1.8% year on year) and operating income of ¥2,431 million (up 2.1% year on year). While structural headwinds continue in the Chinese market due to the advancing preference for domestically produced products, sales of in vitro diagnostic reagents and related products have remained solid. The company also continued to strengthen its business base, with segment assets increasing from ¥22,855 million in the prior year to ¥24,015 million.
Key Products
Growth Drivers
- Continued stable demand for in vitro diagnostic reagents and related products
- Improvement in profit structure through business base strengthening
- Expansion of high-value-added products based on the global niche No. 1 strategy
- Execution of growth investments under the Medium-Term Management Plan (FY2024-FY2027)
Risks
- Impact on sales from the advancing preference for domestically produced products in the Chinese market
- Inability to conduct long-term time-series comparisons under the former classification due to the transition from the former "Life Science Business" to the current "Medical Business"
- Risk of changes in the regulatory environment for pharmaceuticals and medical devices
- Foreign exchange fluctuation risk (given the business structure that includes overseas sales)
Last updated: July 17, 2026

